Zanolimumab
Zanolimumab
Zanolimumab (pronunciation: zan-oh-LIM-yoo-mab) is a monoclonal antibody designed for the treatment of various cancer types. It is a type of immunotherapy that targets the CD4 molecule on the surface of certain white blood cells.
Etymology
The name "Zanolimumab" follows the INN naming convention for monoclonal antibodies, with the suffix "-mab" indicating it is a monoclonal antibody. The prefix "Zano-" does not have a specific meaning in the INN naming convention.
Mechanism of Action
Zanolimumab works by binding to the CD4 molecule on the surface of certain white blood cells. This binding inhibits the growth of these cells, which are often overactive in certain types of cancer.
Clinical Uses
Zanolimumab has been studied for use in the treatment of cutaneous T-cell lymphoma (CTCL), non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL). It has shown promise in early-phase clinical trials, but further research is needed to confirm its efficacy and safety.
Related Terms
- Monoclonal antibody
- Immunotherapy
- CD4
- White blood cells
- Cancer
- Cutaneous T-cell lymphoma
- Non-Hodgkin lymphoma
- Hodgkin lymphoma
External links
- Medical encyclopedia article on Zanolimumab
- Wikipedia's article - Zanolimumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski